Greenwich Biosciences
Global biopharmaceutical company focused on developing and commercializing therapies in neuroscience, oncology and rare diseases. Operates R&D programs from preclinical through late-stage clinical development, runs global clinical trial programs, maintains manufacturing sites for clinical and commercial production, and provides pharmacovigilance and medical information services worldwide.
Industries
Nr. of Employees
small (1-50)
Greenwich Biosciences
Waterloo Exchange, Waterloo Road, Dublin 4, D04 E5W7, Ireland
Products
Cannabidiol oral solution (Epidiolex/Epidyolex)
Plant-derived cannabidiol oral solution indicated for certain treatment-resistant seizure disorders; international regulatory approvals and country-specific prescribing information available.
Sodium oxybate formulations
Oral oxybate products indicated for narcolepsy-related conditions with region-specific prescribing information.
Liposomal daunorubicin + cytarabine (Vyxeos)
Liposomal combination chemotherapy formulation used in certain acute leukemias; developed and commercialized with global labeling and downloadable prescribing information for multiple jurisdictions.
Lurbinectedin
Small-molecule oncology agent evaluated and approved for small cell lung cancer in some markets and studied in combination regimens.
Investigational HER2-targeted bispecific antibody
Bispecific antibody program targeting HER2-expressing solid tumors undergoing multiple Phase 1–3 clinical studies across tumor types.
Investigational mitochondrial protease activator / DRD2 inhibitor (Modeyso/ONC201)
Investigational small molecule under Phase 3 evaluation for a molecularly defined diffuse glioma population; program focuses on mitochondrial protease activation and related mechanisms.
Cannabidiol oral solution (Epidiolex/Epidyolex)
Plant-derived cannabidiol oral solution indicated for certain treatment-resistant seizure disorders; international regulatory approvals and country-specific prescribing information available.
Sodium oxybate formulations
Oral oxybate products indicated for narcolepsy-related conditions with region-specific prescribing information.
Liposomal daunorubicin + cytarabine (Vyxeos)
Liposomal combination chemotherapy formulation used in certain acute leukemias; developed and commercialized with global labeling and downloadable prescribing information for multiple jurisdictions.
Lurbinectedin
Small-molecule oncology agent evaluated and approved for small cell lung cancer in some markets and studied in combination regimens.
Investigational HER2-targeted bispecific antibody
Bispecific antibody program targeting HER2-expressing solid tumors undergoing multiple Phase 1–3 clinical studies across tumor types.
Investigational mitochondrial protease activator / DRD2 inhibitor (Modeyso/ONC201)
Investigational small molecule under Phase 3 evaluation for a molecularly defined diffuse glioma population; program focuses on mitochondrial protease activation and related mechanisms.
Services
Design and execution of multi-phase clinical trials across oncology and neuroscience; clinical trial data sharing and plain-language summaries.
Individual and multiple-patient early access pathways for investigational medicines in line with local regulations.
Region-specific medical information support and global adverse event reporting infrastructure.
Licensing, collaborations and strategic acquisitions with a structured alliance management operating model.
Design and execution of multi-phase clinical trials across oncology and neuroscience; clinical trial data sharing and plain-language summaries.
Individual and multiple-patient early access pathways for investigational medicines in line with local regulations.
Region-specific medical information support and global adverse event reporting infrastructure.
Licensing, collaborations and strategic acquisitions with a structured alliance management operating model.
Expertise Areas
- Clinical trial management
- Oncology drug development
- Neuroscience drug development
- Rare disease therapeutics
Key Technologies
- Bispecific antibody therapeutics
- Liposomal drug delivery
- Small-molecule kinase inhibitors
- Mitochondrial protease activator modalities
News & Updates
Company announced positive Phase 3 results supporting a HER2-targeted bispecific antibody and combination regimens as a new standard of care in first-line HER2-positive gastroesophageal adenocarcinoma.
Company to participate in Citi's 2025 Global Healthcare Conference.
Educational article describing the role of HER2 in certain solid tumors and the value of HER2 testing to inform treatment approaches.
Multiple regulatory approvals, Fast Track and Orphan Drug designations for various oncology and neuroscience products.
Recognition for facility project execution following the opening of the Athlone, Ireland manufacturing and development site.
Company announced positive Phase 3 results supporting a HER2-targeted bispecific antibody and combination regimens as a new standard of care in first-line HER2-positive gastroesophageal adenocarcinoma.
Company to participate in Citi's 2025 Global Healthcare Conference.
Educational article describing the role of HER2 in certain solid tumors and the value of HER2 testing to inform treatment approaches.
Multiple regulatory approvals, Fast Track and Orphan Drug designations for various oncology and neuroscience products.
Recognition for facility project execution following the opening of the Athlone, Ireland manufacturing and development site.